Study on the coagulation function in late-pregnancy women with viral hepatitis and its clinical significance

doi:10.3969/j.issn.1673-8640.2015.03.011

Abstract

Abstract: Objective

To observe the variation of coagulation function and discuss its clinical significance in late-pregnancy women with viral hepatitis.

Methods

A total of 134 late-pregnancy women with viral hepatitis were classified into 5 subgroups: acute hepatitis(39 cases), chronic mild hepatitis(43 cases), chronic moderate/severe hepatitis(25 cases), cirrhosis(15 cases) and severe hepatitis(12 cases) groups. The prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen (FIB) were determined and compared with the results of 45 normal late pregnant women. Meanwhile, the blood coagulation factors, including FⅡ, FⅤ, FⅦ, FⅧ, FⅨ, FⅪ and FⅫ, of 23 chronic mild hepatitis patients, 13 chronic moderate hepatitis patients, 10 cirrhosis patients and 26 normal late pregnant women, were measured respectively.

Results

Compared with normal late pregnancy group, PT and APTT were prolonged in severe hepatitis group (P<0.05). FIB decreased in both cirrhosis group and severe hepatitis group (P<0.05, P<0.01). FⅦ:C in chronic mild hepatitis and chronic moderate hepatitis groups were lower than that in normal pregnant group. Most coagulation factors, except FⅧ:C, in cirrhosis group were lower than those in the normal late-pregnancy group (P<0.05).

Conclusions

Coagulation function in late-pregnancy women is affected with viral hepatitis. It is of great clinical significance to determine the coagulation indices for preventing postnatal hemorrhea and other complications.

Key words: Coagulation, Late pregnancy, Viral hepatitis

CLC Number:

R446.1

FU Jie, ZHANG Rui, XIE Lili, LI Jianwei, DONG Zhiwu. Study on the coagulation function in late-pregnancy women with viral hepatitis and its clinical significance[J]. Laboratory Medicine, 2015, 30(3): 247-249.

Figures/Tables 2

References 12

[1]	中华医学会传染病与寄生虫病学分会,中华医学会肝病学分会. 病毒性肝炎防治方案[J]. 中华传染病杂志, 2001, 19(1):56-62.
[2]	丛玉隆. 关于卫生部出凝血时间操作规程《通知》的理解. 中华检验医学杂志, 2001, 24(3):183-185.
[3]	吴利,周才,黄瑞玉,等. 正常孕妇血浆D-二聚体的检测与分析[J]. 检验医学,2014,29(10):992-994.
[4]	赵世巧,陈忠余,陈大兰,等. 妊娠合并慢性乙型肝炎患者凝血及抗凝和纤溶系统的变化及其临床意义[J]. 中华肝脏病杂志,2012,20(12):942-944.
[5]	徐成伟,范廷英. 正常妊娠妇女凝血、抗凝与纤溶指标的测定及意义[J]. 微循环学杂志,2003,13(2):40-51.
[6]	GRANGER JP,ALEXANDER BT,BENNETT WA,et al. Pathophysiology of pregnancy induced hypertension[J]. Am J Hypertens,2001,14(6 Pt 2):178S-185S.
[7]	梁扩寰,李绍白. 肝脏病学[M]. 2版. 北京:人民卫生出版社,2002:573-580.
[8]	HARISH K,NITHA R,HARIKUMAR R,et al. Prospective evaluation of abnormal liver function tests in pregnancy[J]. Trop Gastroenterol,2005,26(4):188-193
[9]	KOUAKOU F,LOUÉ V,ADJOBY R,et al. Decompensated cirrhosis and pregnancy: a case report[J]. Clin Exp Obstet Gynecol,2012,39(2):252-254
[10]	李琴,贾继东,王宝恩. 凝血酶原时间及凝血因子在肝病中的应用[J]. 中华肝脏病杂志,2004,12(12):767-768.
[11]	HOLLESTELLE MJ,THINNES T,CRAIN K,et al.Tissue distribution of factor VIII gene expression in vivo--a closer look[J]. Thromb Haemost,2001,86(3):855-861.
[12]	陈慧芬,陈杏云,张琴. 病毒性肝炎和妊娠肝炎患者凝血因子和纤溶指标的临床意义[J]. 中华传染病杂志,2005,23(3):191-194.

组别	例数	PT(s)	APTT(s)	FIB(g/L)
正常组	45	10.49±0.64	28.69±3.09	4.07±0.47
急性肝炎组	39	11.25±1.16	28.20±4.04	4.01±0.82
慢性肝炎轻度组	43	10.94±0.81	27.87±3.21	3.72±0.67
慢性肝炎中重度组	25	11.40±1.45	28.06±3.73	3.20±0.54
肝硬化组	15	15.02±1.84	29.54±3.36	2.15±1.32^*
重症肝炎组	12	28.13±5.87^*	50.28±7.42^*	0.91±0.79^**

组别	例数	PT(s)	APTT(s)	FIB(g/L)
正常组	45	10.49±0.64	28.69±3.09	4.07±0.47
急性肝炎组	39	11.25±1.16	28.20±4.04	4.01±0.82
慢性肝炎轻度组	43	10.94±0.81	27.87±3.21	3.72±0.67
慢性肝炎中重度组	25	11.40±1.45	28.06±3.73	3.20±0.54
肝硬化组	15	15.02±1.84	29.54±3.36	2.15±1.32^*
重症肝炎组	12	28.13±5.87^*	50.28±7.42^*	0.91±0.79^**

组别	例数	FⅡ:C	FⅤ:C	FⅦ:C	FⅧ:C	FⅨ:C	FⅪ:C	FⅫ:C
正常晚孕组	26	177.8±40.6	175.8±35.7	283.5±56.7	243.4±96.1	141.8±47.2	73.4±9.7	121.3±25.4
慢性肝炎轻度组	23	162.9±28.1	165.7±40.8	213.1±68.5^*	239.5±74.3	147.3±34.8	70.7±16.9	107.4±27.3
慢性肝炎中重度组	13	86.7±57.3	85.9±68.4	159.7±81.5^*	228.8±67.5	105.3±49.6	65.5±27.2	78.2±38.6
肝硬化组	10	74.3±51.5^*	65.7±35.4^*	79.5±40.2^*	294.2±82.4^*	77.3±32.9^*	58.5±15.4^*	66.8±41.1^*

组别	例数	FⅡ:C	FⅤ:C	FⅦ:C	FⅧ:C	FⅨ:C	FⅪ:C	FⅫ:C
正常晚孕组	26	177.8±40.6	175.8±35.7	283.5±56.7	243.4±96.1	141.8±47.2	73.4±9.7	121.3±25.4
慢性肝炎轻度组	23	162.9±28.1	165.7±40.8	213.1±68.5^*	239.5±74.3	147.3±34.8	70.7±16.9	107.4±27.3
慢性肝炎中重度组	13	86.7±57.3	85.9±68.4	159.7±81.5^*	228.8±67.5	105.3±49.6	65.5±27.2	78.2±38.6
肝硬化组	10	74.3±51.5^*	65.7±35.4^*	79.5±40.2^*	294.2±82.4^*	77.3±32.9^*	58.5±15.4^*	66.8±41.1^*

[1]	SHI Shaoxin, CHEN Xueting, XU Xiaofeng, LU Renquan, GUO Lin, ZHUANG Yihui. Role of coagulation function in bacterial bloodstream infection among malignant tumor patients [J]. Laboratory Medicine, 2025, 40(8): 804-809.
[2]	JIANG Fengying, JIANG Yun, MI Rui, QIAN Ximing, WANG Qiubo. Changes of platelet and coagulation function indicators in elderly patients with diabetic foot ulcers [J]. Laboratory Medicine, 2025, 40(7): 708-712.
[3]	YANG Qi, LIN Ying, GUO Nan, LI Xiaobin, SHANG E, LI Hongmin, YAO Xingwei. Changes of coagulation function in elderly patients with severe pneumonia infected by different Gram-negative bacteria [J]. Laboratory Medicine, 2025, 40(6): 560-564.
[4]	WANG Chengyun, GU Ping, PAN Qiuhui, WANG Jing. Changes and clinical value of blood coagulation indexes in children with infection [J]. Laboratory Medicine, 2025, 40(2): 178-181.
[5]	XU Fei, CHEN Zhujun, YU Liang, ZHANG Jing, LU Renquan, GUO Lin, ZHUANG Yihui. Analysis of etiological characteristics and death risk factors of candidemia in tumor patients [J]. Laboratory Medicine, 2024, 39(9): 888-894.
[6]	ZHAO Chunhe, SHAO Huihui, CUI Weiqi, XIA Wei, QU Linlin. Progress in application of blood coagulation point-of-care testing [J]. Laboratory Medicine, 2024, 39(7): 709-714.
[7]	JIANG Jingjing, GU Ping, WANG Chengyun, ZHANG Fan, SHEN Huiying, PAN Qiuhui, WANG Jing. Changes and clinical significance of procalcitonin and coagulation function indicators in children with sepsis [J]. Laboratory Medicine, 2024, 39(6): 573-577.
[8]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.
[9]	XIA Yanyan, XIA Yongquan, SONG Guanghao, XIA Mao. Role of coagulation-related monitoring indicators in the course of rivaroxaban anticoagulation for acute venous thromboembolism in elderly patients [J]. Laboratory Medicine, 2023, 38(5): 475-478.
[10]	FAN Qingkun, LI Ling, DU Jia, YANG Jun, ZHANG Zhenlu. Problems and solutions on autoverification of coagulation test [J]. Laboratory Medicine, 2022, 37(6): 596-600.
[11]	LI Keke, XIAO Yang. Research progress of coagulation factor Ⅴ and its association with hemorrhage and thrombosis [J]. Laboratory Medicine, 2022, 37(4): 396-399.
[12]	XIE Yuan, YI Wanwan, SHI Qiuyuan, LÜ Zhongwei, LIU Jin. Clinical value of thromboelastography and conventional coagulation tests in evaluating coagulation status of colon cancer and colon polyps [J]. Laboratory Medicine, 2022, 37(11): 1007-1011.
[13]	SUN Yuehong, ZHANG Limin, LI Xiao, WANG Dan, WU Jing, LI Yuwen, ZHANG Guojun. Correlation between TEG and DIC and its diagnostic value [J]. Laboratory Medicine, 2021, 36(5): 495-499.
[14]	XIE Hui, SHEN Han. Changes of coagulation function and influence factors of hypercoagulability in patients with chronic kidney disease [J]. Laboratory Medicine, 2021, 36(5): 500-503.
[15]	ZHENG Xin, HU Jun, ZHANG Xueqing, ZHANG Jun, YAO Dongting, HU Xiaobo. Application of six sigma management in shortening outpatient coagulation test's turn-around time in clinical laboratory [J]. Laboratory Medicine, 2021, 36(11): 1177-1180.